Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
CTR20221015Phase 4Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Flumatinib and imatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Major molecular response rate at 12 months. Started May 2022; status: active.
02
Drugs
Flumatinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20221015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221015.